RedHill Biopharma (RDHL) Equity Average: 2019-2025
- RedHill Biopharma's Equity Average fell 3.63% to -$211.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$211.4 million, marking a year-over-year decrease of 3.63%. This contributed to the annual value of -$1.3 million for FY2024, which is 94.36% up from last year.
- RedHill Biopharma's Equity Average amounted to -$211.4 million in Q2 2025, which was down 1.94% from -$207.4 million recorded in Q4 2024.
- In the past 5 years, RedHill Biopharma's Equity Average ranged from a high of -$190.0 million in Q4 2023 and a low of -$211.4 million during Q2 2025.
- For the 3-year period, RedHill Biopharma's Equity Average averaged around -$203.2 million, with its median value being -$205.7 million (2024).
- Data for RedHill Biopharma's Equity Average shows a maximum YoY dropped of 9.16% (in 2024) over the last 5 years.
- RedHill Biopharma's Equity Average (Quarterly) stood at -$190.0 million in 2023, then dropped by 9.16% to -$207.4 million in 2024, then dropped by 3.63% to -$211.4 million in 2025.
- Its last three reported values are -$211.4 million in Q2 2025, -$207.4 million for Q4 2024, and -$204.0 million during Q2 2024.
